Industry Research Reports

Home > Reports > Medical Care > Global Rheumatoid Arthritis (RA) Drugs Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Global Rheumatoid Arthritis (RA) Drugs Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Industry: Medical Care

Published Date: 2025-09-06

Pages: 92 Pages

Report ld: 4990029

Request Sample

Pre-Order Enquiry

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global Rheumatoid Arthritis (RA) Drugs market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.

Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The global Rheumatoid Arthritis (RA) Drugs market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.

Market Segmentation

By Company

AbbVie
Roche
Merck
HEYL Chemisch-pharmazeutische Fabrik
Johnson & Johnson
Amgen, Inc.
Pfizer
Bristol-Myers Squibb
UCB
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

NSAIDs
Analgesic Drugs
Corticosteroids
DMARDs
Biological Therapies
JAK-inhibitors

Segment by Application

Hospitals
Clinics
Others

biaoTi Chapter Outline

Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).

Chapter 2: Quantitative analysis of Rheumatoid Arthritis (RA) Drugs market size and growth potential at global, regional, and country levels.

Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).

Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Analgesic Drugs in China).

Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Clinics in India).

Chapter 6: Regional revenue breakdown by company, type, application and customer.

Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.

Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.

Chapter 9: Actionable conclusions and strategic recommendations.

biaoTi Why This Report?

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

Table of Contents

1 Report Overview

1.1 Study Scope

1.2 Market by Type

1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031

1.2.2 NSAIDs

1.2.3 Analgesic Drugs

1.2.4 Corticosteroids

1.2.5 DMARDs

1.2.6 Biological Therapies

1.2.7 JAK-inhibitors

1.3 Market by Application

1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Rheumatoid Arthritis (RA) Drugs Market Perspective (2020-2031)

2.2 Global Market Size by Region: 2020 VS 2024 VS 2031

2.3 Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Region (2020-2025)

2.4 Global Rheumatoid Arthritis (RA) Drugs Revenue Forecast by Region (2026-2031)

2.5 Major Region and Emerging Market Analysis

2.5.1 North America Rheumatoid Arthritis (RA) Drugs Market Size and Prospective (2020-2031)

2.5.2 Europe Rheumatoid Arthritis (RA) Drugs Market Size and Prospective (2020-2031)

2.5.3 China Rheumatoid Arthritis (RA) Drugs Market Size and Prospective (2020-2031)

2.5.4 Japan Rheumatoid Arthritis (RA) Drugs Market Size and Prospective (2020-2031)

2.5.5 Southeast Asia Rheumatoid Arthritis (RA) Drugs Market Size and Prospective (2020-2031)

2.5.6 India Rheumatoid Arthritis (RA) Drugs Market Size and Prospective (2020-2031)

2.5.7 Central & South America Rheumatoid Arthritis (RA) Drugs Market Size and Prospective (2020-2031)

3 Breakdown Data by Type

3.1 Global Rheumatoid Arthritis (RA) Drugs Historic Market Size by Type (2020-2025)

3.2 Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Type (2026-2031)

3.3 Different Types Rheumatoid Arthritis (RA) Drugs Representative Players

4 Breakdown Data by Application

4.1 Global Rheumatoid Arthritis (RA) Drugs Historic Market Size by Application (2020-2025)

4.2 Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Application (2026-2031)

4.3 New Sources of Growth in Rheumatoid Arthritis (RA) Drugs Application

5 Competition Landscape by Players

5.1 Global Top Players by Revenue

5.1.1 Global Top Rheumatoid Arthritis (RA) Drugs Players by Revenue (2020-2025)

5.1.2 Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Players (2020-2025)

5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

5.3 Players Covered: Ranking by Rheumatoid Arthritis (RA) Drugs Revenue

5.4 Global Rheumatoid Arthritis (RA) Drugs Market Concentration Analysis

5.4.1 Global Rheumatoid Arthritis (RA) Drugs Market Concentration Ratio (CR5 and HHI)

5.4.2 Global Top 10 and Top 5 Companies by Rheumatoid Arthritis (RA) Drugs Revenue in 2024

5.5 Global Key Players of Rheumatoid Arthritis (RA) Drugs Head office and Area Served

5.6 Global Key Players of Rheumatoid Arthritis (RA) Drugs, Product and Application

5.7 Global Key Players of Rheumatoid Arthritis (RA) Drugs, Date of Enter into This Industry

5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis

6.1 North America Market: Players, Segments and Downstream

6.1.1 North America Rheumatoid Arthritis (RA) Drugs Revenue by Company (2020-2025)

6.1.2 North America Market Size by Type

6.1.2.1 North America Rheumatoid Arthritis (RA) Drugs Market Size by Type (2020-2025)

6.1.2.2 North America Rheumatoid Arthritis (RA) Drugs Market Share by Type (2020-2025)

6.1.3 North America Market Size by Application

6.1.3.1 North America Rheumatoid Arthritis (RA) Drugs Market Size by Application (2020-2025)

6.1.3.2 North America Rheumatoid Arthritis (RA) Drugs Market Share by Application (2020-2025)

6.1.4 North America Market Trend and Opportunities

6.2 Europe Market: Players, Segments and Downstream

6.2.1 Europe Rheumatoid Arthritis (RA) Drugs Revenue by Company (2020-2025)

6.2.2 Europe Market Size by Type

6.2.2.1 Europe Rheumatoid Arthritis (RA) Drugs Market Size by Type (2020-2025)

6.2.2.2 Europe Rheumatoid Arthritis (RA) Drugs Market Share by Type (2020-2025)

6.2.3 Europe Market Size by Application

6.2.3.1 Europe Rheumatoid Arthritis (RA) Drugs Market Size by Application (2020-2025)

6.2.3.2 Europe Rheumatoid Arthritis (RA) Drugs Market Share by Application (2020-2025)

6.2.4 Europe Market Trend and Opportunities

6.3 China Market: Players, Segments and Downstream

6.3.1 China Rheumatoid Arthritis (RA) Drugs Revenue by Company (2020-2025)

6.3.2 China Market Size by Type

6.3.2.1 China Rheumatoid Arthritis (RA) Drugs Market Size by Type (2020-2025)

6.3.2.2 China Rheumatoid Arthritis (RA) Drugs Market Share by Type (2020-2025)

6.3.3 China Market Size by Application

6.3.3.1 China Rheumatoid Arthritis (RA) Drugs Market Size by Application (2020-2025)

6.3.3.2 China Rheumatoid Arthritis (RA) Drugs Market Share by Application (2020-2025)

6.3.4 China Market Trend and Opportunities

6.4 Japan Market: Players, Segments and Downstream

6.4.1 Japan Rheumatoid Arthritis (RA) Drugs Revenue by Company (2020-2025)

6.4.2 Japan Market Size by Type

6.4.2.1 Japan Rheumatoid Arthritis (RA) Drugs Market Size by Type (2020-2025)

6.4.2.2 Japan Rheumatoid Arthritis (RA) Drugs Market Share by Type (2020-2025)

6.4.3 Japan Market Size by Application

6.4.3.1 Japan Rheumatoid Arthritis (RA) Drugs Market Size by Application (2020-2025)

6.4.3.2 Japan Rheumatoid Arthritis (RA) Drugs Market Share by Application (2020-2025)

6.4.4 Japan Market Trend and Opportunities

6.5 Southeast Asia Market: Players, Segments and Downstream

6.5.1 Southeast Asia Rheumatoid Arthritis (RA) Drugs Revenue by Company (2020-2025)

6.5.2 Southeast Asia Market Size by Type

6.5.2.1 Southeast Asia Rheumatoid Arthritis (RA) Drugs Market Size by Type (2020-2025)

6.5.2.2 Southeast Asia Rheumatoid Arthritis (RA) Drugs Market Share by Type (2020-2025)

6.5.3 Southeast Asia Market Size by Application

6.5.3.1 Southeast Asia Rheumatoid Arthritis (RA) Drugs Market Size by Application (2020-2025)

6.5.3.2 Southeast Asia Rheumatoid Arthritis (RA) Drugs Market Share by Application (2020-2025)

6.5.4 Southeast Asia Market Trend and Opportunities

6.6 India Market: Players, Segments and Downstream

6.6.1 India Rheumatoid Arthritis (RA) Drugs Revenue by Company (2020-2025)

6.6.2 India Market Size by Type

6.6.2.1 India Rheumatoid Arthritis (RA) Drugs Market Size by Type (2020-2025)

6.6.2.2 India Rheumatoid Arthritis (RA) Drugs Market Share by Type (2020-2025)

6.6.3 India Market Size by Application

6.6.3.1 India Rheumatoid Arthritis (RA) Drugs Market Size by Application (2020-2025)

6.6.3.2 India Rheumatoid Arthritis (RA) Drugs Market Share by Application (2020-2025)

6.6.4 India Market Trend and Opportunities

7 Key Players Profiles

7.1 AbbVie

7.1.1 AbbVie Company Details

7.1.2 AbbVie Business Overview

7.1.3 AbbVie Rheumatoid Arthritis (RA) Drugs Introduction

7.1.4 AbbVie Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

7.1.5 AbbVie Recent Development

7.2 Roche

7.2.1 Roche Company Details

7.2.2 Roche Business Overview

7.2.3 Roche Rheumatoid Arthritis (RA) Drugs Introduction

7.2.4 Roche Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

7.2.5 Roche Recent Development

7.3 Merck

7.3.1 Merck Company Details

7.3.2 Merck Business Overview

7.3.3 Merck Rheumatoid Arthritis (RA) Drugs Introduction

7.3.4 Merck Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

7.3.5 Merck Recent Development

7.4 HEYL Chemisch-pharmazeutische Fabrik

7.4.1 HEYL Chemisch-pharmazeutische Fabrik Company Details

7.4.2 HEYL Chemisch-pharmazeutische Fabrik Business Overview

7.4.3 HEYL Chemisch-pharmazeutische Fabrik Rheumatoid Arthritis (RA) Drugs Introduction

7.4.4 HEYL Chemisch-pharmazeutische Fabrik Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

7.4.5 HEYL Chemisch-pharmazeutische Fabrik Recent Development

7.5 Johnson & Johnson

7.5.1 Johnson & Johnson Company Details

7.5.2 Johnson & Johnson Business Overview

7.5.3 Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Introduction

7.5.4 Johnson & Johnson Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

7.5.5 Johnson & Johnson Recent Development

7.6 Amgen, Inc.

7.6.1 Amgen, Inc. Company Details

7.6.2 Amgen, Inc. Business Overview

7.6.3 Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Introduction

7.6.4 Amgen, Inc. Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

7.6.5 Amgen, Inc. Recent Development

7.7 Pfizer

7.7.1 Pfizer Company Details

7.7.2 Pfizer Business Overview

7.7.3 Pfizer Rheumatoid Arthritis (RA) Drugs Introduction

7.7.4 Pfizer Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

7.7.5 Pfizer Recent Development

7.8 Bristol-Myers Squibb

7.8.1 Bristol-Myers Squibb Company Details

7.8.2 Bristol-Myers Squibb Business Overview

7.8.3 Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Introduction

7.8.4 Bristol-Myers Squibb Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

7.8.5 Bristol-Myers Squibb Recent Development

7.9 UCB

7.9.1 UCB Company Details

7.9.2 UCB Business Overview

7.9.3 UCB Rheumatoid Arthritis (RA) Drugs Introduction

7.9.4 UCB Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

7.9.5 UCB Recent Development

7.10 GSK

7.10.1 GSK Company Details

7.10.2 GSK Business Overview

7.10.3 GSK Rheumatoid Arthritis (RA) Drugs Introduction

7.10.4 GSK Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

7.10.5 GSK Recent Development

7.11 Sanofi

7.11.1 Sanofi Company Details

7.11.2 Sanofi Business Overview

7.11.3 Sanofi Rheumatoid Arthritis (RA) Drugs Introduction

7.11.4 Sanofi Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

7.11.5 Sanofi Recent Development

7.12 Abbott Laboratories

7.12.1 Abbott Laboratories Company Details

7.12.2 Abbott Laboratories Business Overview

7.12.3 Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Introduction

7.12.4 Abbott Laboratories Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

7.12.5 Abbott Laboratories Recent Development

7.13 Teva Pharmaceutical

7.13.1 Teva Pharmaceutical Company Details

7.13.2 Teva Pharmaceutical Business Overview

7.13.3 Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Introduction

7.13.4 Teva Pharmaceutical Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

7.13.5 Teva Pharmaceutical Recent Development

8 Rheumatoid Arthritis (RA) Drugs Market Dynamics

8.1 Rheumatoid Arthritis (RA) Drugs Industry Trends

8.2 Rheumatoid Arthritis (RA) Drugs Market Drivers

8.3 Rheumatoid Arthritis (RA) Drugs Market Challenges

8.4 Rheumatoid Arthritis (RA) Drugs Market Restraints

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

Table of Figures

List of Tables

Table 1. Global Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Global Rheumatoid Arthritis (RA) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 3. Global Market Rheumatoid Arthritis (RA) Drugs Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Table 4. Global Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) Market Share by Region (2020-2025)

Table 5. Global Rheumatoid Arthritis (RA) Drugs Revenue Share by Region (2020-2025)

Table 6. Global Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) Forecast by Region (2026-2031)

Table 7. Global Rheumatoid Arthritis (RA) Drugs Revenue Share Forecast by Region (2026-2031)

Table 8. Global Rheumatoid Arthritis (RA) Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 9. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Type (2020-2025)

Table 10. Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 11. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Type (2026-2031)

Table 12. Representative Players of Each Type

Table 13. Global Rheumatoid Arthritis (RA) Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 14. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Application (2020-2025)

Table 15. Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 16. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Application (2026-2031)

Table 17. New Sources of Growth in Rheumatoid Arthritis (RA) Drugs Application

Table 18. Global Rheumatoid Arthritis (RA) Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 19. Global Rheumatoid Arthritis (RA) Drugs Market Share by Players (2020-2025)

Table 20. Global Top Rheumatoid Arthritis (RA) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rheumatoid Arthritis (RA) Drugs as of 2024)

Table 21. Ranking of Global Top Rheumatoid Arthritis (RA) Drugs Companies by Revenue (US$ Million) in 2024

Table 22. Global 5 Largest Players Market Share by Rheumatoid Arthritis (RA) Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 23. Global Key Players of Rheumatoid Arthritis (RA) Drugs, Headquarters and Area Served

Table 24. Global Key Players of Rheumatoid Arthritis (RA) Drugs, Product and Application

Table 25. Global Key Players of Rheumatoid Arthritis (RA) Drugs, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. North America Rheumatoid Arthritis (RA) Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 28. North America Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Company (2020-2025)

Table 29. North America Rheumatoid Arthritis (RA) Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 30. North America Rheumatoid Arthritis (RA) Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 31. Europe Rheumatoid Arthritis (RA) Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 32. Europe Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Company (2020-2025)

Table 33. Europe Rheumatoid Arthritis (RA) Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 34. Europe Rheumatoid Arthritis (RA) Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 35. China Rheumatoid Arthritis (RA) Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 36. China Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Company (2020-2025)

Table 37. China Rheumatoid Arthritis (RA) Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 38. China Rheumatoid Arthritis (RA) Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 39. Japan Rheumatoid Arthritis (RA) Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 40. Japan Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Company (2020-2025)

Table 41. Japan Rheumatoid Arthritis (RA) Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 42. Japan Rheumatoid Arthritis (RA) Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 43. Southeast Asia Rheumatoid Arthritis (RA) Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 44. Southeast Asia Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Company (2020-2025)

Table 45. Southeast Asia Rheumatoid Arthritis (RA) Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 46. Southeast Asia Rheumatoid Arthritis (RA) Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 47. India Rheumatoid Arthritis (RA) Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 48. India Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Company (2020-2025)

Table 49. India Rheumatoid Arthritis (RA) Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 50. India Rheumatoid Arthritis (RA) Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 51. AbbVie Company Details

Table 52. AbbVie Business Overview

Table 53. AbbVie Rheumatoid Arthritis (RA) Drugs Product

Table 54. AbbVie Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025) & (US$ Million)

Table 55. AbbVie Recent Development

Table 56. Roche Company Details

Table 57. Roche Business Overview

Table 58. Roche Rheumatoid Arthritis (RA) Drugs Product

Table 59. Roche Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025) & (US$ Million)

Table 60. Roche Recent Development

Table 61. Merck Company Details

Table 62. Merck Business Overview

Table 63. Merck Rheumatoid Arthritis (RA) Drugs Product

Table 64. Merck Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025) & (US$ Million)

Table 65. Merck Recent Development

Table 66. HEYL Chemisch-pharmazeutische Fabrik Company Details

Table 67. HEYL Chemisch-pharmazeutische Fabrik Business Overview

Table 68. HEYL Chemisch-pharmazeutische Fabrik Rheumatoid Arthritis (RA) Drugs Product

Table 69. HEYL Chemisch-pharmazeutische Fabrik Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025) & (US$ Million)

Table 70. HEYL Chemisch-pharmazeutische Fabrik Recent Development

Table 71. Johnson & Johnson Company Details

Table 72. Johnson & Johnson Business Overview

Table 73. Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Product

Table 74. Johnson & Johnson Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025) & (US$ Million)

Table 75. Johnson & Johnson Recent Development

Table 76. Amgen, Inc. Company Details

Table 77. Amgen, Inc. Business Overview

Table 78. Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Product

Table 79. Amgen, Inc. Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025) & (US$ Million)

Table 80. Amgen, Inc. Recent Development

Table 81. Pfizer Company Details

Table 82. Pfizer Business Overview

Table 83. Pfizer Rheumatoid Arthritis (RA) Drugs Product

Table 84. Pfizer Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025) & (US$ Million)

Table 85. Pfizer Recent Development

Table 86. Bristol-Myers Squibb Company Details

Table 87. Bristol-Myers Squibb Business Overview

Table 88. Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Product

Table 89. Bristol-Myers Squibb Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025) & (US$ Million)

Table 90. Bristol-Myers Squibb Recent Development

Table 91. UCB Company Details

Table 92. UCB Business Overview

Table 93. UCB Rheumatoid Arthritis (RA) Drugs Product

Table 94. UCB Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025) & (US$ Million)

Table 95. UCB Recent Development

Table 96. GSK Company Details

Table 97. GSK Business Overview

Table 98. GSK Rheumatoid Arthritis (RA) Drugs Product

Table 99. GSK Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025) & (US$ Million)

Table 100. GSK Recent Development

Table 101. Sanofi Company Details

Table 102. Sanofi Business Overview

Table 103. Sanofi Rheumatoid Arthritis (RA) Drugs Product

Table 104. Sanofi Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025) & (US$ Million)

Table 105. Sanofi Recent Development

Table 106. Abbott Laboratories Company Details

Table 107. Abbott Laboratories Business Overview

Table 108. Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Product

Table 109. Abbott Laboratories Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025) & (US$ Million)

Table 110. Abbott Laboratories Recent Development

Table 111. Teva Pharmaceutical Company Details

Table 112. Teva Pharmaceutical Business Overview

Table 113. Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Product

Table 114. Teva Pharmaceutical Revenue in Rheumatoid Arthritis (RA) Drugs Business (2020-2025) & (US$ Million)

Table 115. Teva Pharmaceutical Recent Development

Table 116. Rheumatoid Arthritis (RA) Drugs Market Trends

Table 117. Rheumatoid Arthritis (RA) Drugs Market Drivers

Table 118. Rheumatoid Arthritis (RA) Drugs Market Challenges

Table 119. Rheumatoid Arthritis (RA) Drugs Market Restraints

Table 120. Research Programs/Design for This Report

Table 121. Key Data Information from Secondary Sources

Table 122. Key Data Information from Primary Sources

List of Figures

Figure 1. Rheumatoid Arthritis (RA) Drugs Product Picture

Figure 2. Global Rheumatoid Arthritis (RA) Drugs Market Share by Type: 2024 VS 2031

Figure 3. NSAIDs Features

Figure 4. Analgesic Drugs Features

Figure 5. Corticosteroids Features

Figure 6. DMARDs Features

Figure 7. Biological Therapies Features

Figure 8. JAK-inhibitors Features

Figure 9. Global Rheumatoid Arthritis (RA) Drugs Market Share by Application: 2024 VS 2031

Figure 10. Hospitals

Figure 11. Clinics

Figure 12. Others

Figure 13. Rheumatoid Arthritis (RA) Drugs Report Years Considered

Figure 14. Global Rheumatoid Arthritis (RA) Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Rheumatoid Arthritis (RA) Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Region: 2020 VS 2024

Figure 17. North America Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 18. Europe Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 19. China Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 20. Japan Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 21. Southeast Asia Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 22. India Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 23. Central & South America Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 24. Global Rheumatoid Arthritis (RA) Drugs Market Share by Players in 2024

Figure 25. Global Top Rheumatoid Arthritis (RA) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rheumatoid Arthritis (RA) Drugs as of 2024)

Figure 26. The Top 10 and 5 Players Market Share by Rheumatoid Arthritis (RA) Drugs Revenue in 2024

Figure 27. North America Rheumatoid Arthritis (RA) Drugs Market Share by Type (2020-2025)

Figure 28. North America Rheumatoid Arthritis (RA) Drugs Market Share by Application (2020-2025)

Figure 29. Europe Rheumatoid Arthritis (RA) Drugs Market Share by Type (2020-2025)

Figure 30. Europe Rheumatoid Arthritis (RA) Drugs Market Share by Application (2020-2025)

Figure 31. China Rheumatoid Arthritis (RA) Drugs Market Share by Type (2020-2025)

Figure 32. China Rheumatoid Arthritis (RA) Drugs Market Share by Application (2020-2025)

Figure 33. Japan Rheumatoid Arthritis (RA) Drugs Market Share by Type (2020-2025)

Figure 34. Japan Rheumatoid Arthritis (RA) Drugs Market Share by Application (2020-2025)

Figure 35. Southeast Asia Rheumatoid Arthritis (RA) Drugs Market Share by Type (2020-2025)

Figure 36. Southeast Asia Rheumatoid Arthritis (RA) Drugs Market Share by Application (2020-2025)

Figure 37. India Rheumatoid Arthritis (RA) Drugs Market Share by Type (2020-2025)

Figure 38. India Rheumatoid Arthritis (RA) Drugs Market Share by Application (2020-2025)

Figure 39. AbbVie Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

Figure 40. Roche Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

Figure 41. Merck Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

Figure 42. HEYL Chemisch-pharmazeutische Fabrik Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

Figure 43. Johnson & Johnson Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

Figure 44. Amgen, Inc. Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

Figure 45. Pfizer Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

Figure 46. Bristol-Myers Squibb Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

Figure 47. UCB Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

Figure 48. GSK Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

Figure 49. Sanofi Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

Figure 50. Abbott Laboratories Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

Figure 51. Teva Pharmaceutical Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2020-2025)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

Figure 54. Key Executives Interviewed

Related Reports

Rheumatoid Arthritis (RA) Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
Published Date: 2024-01-24
Pages: 101
USD 3950.00
(Single User License)
Global Rheumatoid Arthritis (RA) Drugs Market Research Report 2024
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
Published Date: 2024-01-31
Pages: 87
USD 2900.00
(Single User License)
Global Rheumatoid Arthritis (RA) Drugs Market Insights, Forecast to 2030
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
Published Date: 2024-04-26
Pages: 107
USD 4900.00
(Single User License)
Global Rheumatoid Arthritis (RA) Drugs Market Research Report 2025
The global market for Rheumatoid Arthritis (RA) Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-27
Pages: 85
USD 2900.00
(Single User License)
Rheumatoid Arthritis (RA) Drugs- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Rheumatoid Arthritis (RA) Drugs was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-27
Pages: 120
USD 3950.00
(Single User License)
Global Rheumatoid Arthritis (RA) Drugs Market Research Report 2026
The global Rheumatoid Arthritis (RA) Drugs market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-04-27
Pages: 118
USD 2900.00
(Single User License)
Rheumatoid Arthritis (RA) Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Rheumatoid Arthritis (RA) Drugs was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-07-14
Pages: 111
USD 3950.00
(Single User License)

Rheumatoid Arthritis (RA) Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
Published: 2024-01-24
Pages: 101
USD 3950.00 (Single User License)
Global Rheumatoid Arthritis (RA) Drugs Market Research Report 2024
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
Published: 2024-01-31
Pages: 87
USD 2900.00 (Single User License)
Global Rheumatoid Arthritis (RA) Drugs Market Insights, Forecast to 2030
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
Published: 2024-04-26
Pages: 107
USD 4900.00 (Single User License)
Global Rheumatoid Arthritis (RA) Drugs Market Research Report 2025
The global market for Rheumatoid Arthritis (RA) Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-27
Pages: 85
USD 2900.00 (Single User License)
Rheumatoid Arthritis (RA) Drugs- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Rheumatoid Arthritis (RA) Drugs was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-27
Pages: 120
USD 3950.00 (Single User License)
Global Rheumatoid Arthritis (RA) Drugs Market Research Report 2026
The global Rheumatoid Arthritis (RA) Drugs market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-04-27
Pages: 118
USD 2900.00 (Single User License)
Rheumatoid Arthritis (RA) Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Rheumatoid Arthritis (RA) Drugs was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-07-14
Pages: 111
USD 3950.00 (Single User License)